Condition
Cutaneous Melanoma, Stage III
Total Trials
7
Recruiting
3
Active
3
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 7 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
Early P 1 (1)
P 2 (3)
Trial Status
Completed3
Recruiting3
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT03719131Phase 2CompletedPrimary
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
NCT07230613Phase 2RecruitingPrimary
Neo-adjuvant Immunotherapy in Patients With Localized Melanoma
NCT07049276Not ApplicableRecruitingPrimary
The Multicentre Selective Lymphadenectomy Trial - 3
NCT07148245Recruiting
Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
NCT04853602UnknownPrimary
IFx-Hu2.0 Expanded Access Program
NCT03655756Early Phase 1CompletedPrimary
pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma
NCT03541148Phase 2Completed
Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma
Showing all 7 trials